People with a learning disability are often disadvantaged due to the nature of their disability. Up to a third are likely to have concomitant epilepsy which adds to the health loss experienced by this group. It is important to manage their epjlepsy in such a way as to limit the debilitating effects of both the illness and the medication. Rectal diazepam remains the gold standard rescue medication for prolonged, recurrent seizures or seizures associated with hypoxia. Some of the drawbacks are highlighted in this paper and we go on to explore a novel means of treating these seizures. Midazolam, via the intranasal route, has been used extensively in children, mostly as a sedative but also in the treatment of epilepsy. We present two cases, both are adults with a learning disability, who have benefited significantly from the use of intranasal midazolam. Ongoing research into the safe use of this form of treatment, training of staff and carers and the impact on the individual is being conducted.
INTRODUCTION
A learning disability is a clinical entity defined by statistics. The population with a learning disability is very heterogeneous, but the precise definition of an individual with a learning disability (according to the American Diagnostic and Statistical Manual for Psychiatric Disorder) is a person who has an IQ of less than 70 and whose ability to adapt and survive within society is limited'.
In addition to their learning disability, 15-30% will have epilepsy. In general, the more severe the degree of learning disability the more likely the possibility of epilepsy occurring and, in addition, their seizures are often of a severe and complex nature*. The diagnosis and management of their epilepsy is complicated by problems with communication, difficulties with cooperation for investigations and a general failure on the part of carers and health professionals alike to recognise the more subtle forms of seizure3.
Epilepsy is a significant cause of health loss in the learning disabled population and it is of concern that some are not able to access the local facilities because of the chance that they might have a prolonged seizure and require medication whilst out. *E-mail: mscheepsbaol.com 5 E-mail: brucesQdavidlewis.org.uk A seizure is considered to be prolonged if it lasts longer than 5 minutes or if there are two or more consecutive seizures of shorter duration without a return to consciousness between these seizures. Some patients may have a cluster of seizures following the initial seizure whilst others may have hypoxic episodes during the tonic phase leading to cyanosis.
MATERIALS AND METHODS

Current practice
Rectal diazepam is the current gold standard for the treatment of prolonged seizures and although an effective treatment for many patients it does have drawbacks. The variable nature of the absorption of the drug when administered rectally, carers' attitudes to rectal administration and the embarrassment to the patient compound difficulties with its use. Furthermore, the long half-life (20-40 hours) can lead to prolonged sedation as an unwanted side effect". This drowsiness may have the paradoxical effect of lowering the seizure threshold making the patient more susceptible to further seizures.
Other problems with this treatment are fairly common as reported by both carers and patients. Fear of rectal Diazepam administration has been cited as a rea-1059-l 3111981060509 + 04 $12.00/O @ 1996 British Epilepsy Association son for truancy among older children with epilepsy, embarrassment following the administration of a rectal drug is described, some carers feel that this is a form of sexual abuse and it is an unacceptable treatment to administer in a public place3. Many local authority carers refuse to administer rectal medication, schoolteachers are reluctant to use this form of treatment unless supervised, whilst other carers have difficulty administering this medication despite adequate training6.
With the resettlement of people with a learning disability back into the community it has become essential to look for other methods of emergency treatment and alternative routes of administration which would allow the individual to access the community with as little restriction as is possible3.
Diazepam was one of the earliest benzodiazepines first used in 1962. It is highly lipid soluble and so diffuses rapidly into the central nervous system but equally its high lipid solubility means that it is stored in body fat so that it has a high volume of distribution affecting its elimination'. It has been used both intravenously and rectally*. Intramuscular absorption has been too variable and has not been recommended for treatment of seizures3. Both midazolam and clonazepam have been used intravenously, intramuscularly and orally for the short term management of seizures3.
Alternative practice
Easily accessible options for the delivery of drugs in the acute situation are the nasopharangeal and the sublingual mucosal surfaces 's9. Midazolam via this route is widely used in anaesthetic practice*, lo, 1 t , particularly in children 12-t5. This has prompted the use of intranasal and sublingual midazolam in the treatment of seizure disorders in childret& *&t8.
There would appear to be further value in its use as a sedative agent in people with a learning disability who are undergoing procedures'9*20 as it can be safely administered via the intranasal or sublingual routes 13. There have been numerous studies confirming its efficacy and comparing the differences between intravenous, intranasal or intramuscular adfinis&ation'ov II*15**1.**.
Midazolam is a water-soluble, short-acting, benzodiazepine introduced into clinical practice in 1982. It is commonly used in anaesthetic practice where its value as a pre-medication is well documented. It is rapidly absorbed from oral, intramuscular and intravenous routes with significant anxiolytic, sedative and anterograde amnesic effects5.
The pharmacology and pharmacokinetics are well known. It is an imidazobenzodiazepine with an open structure maintained whilst in an acidic suspension. At physiological pH the ring structure closes and the drug becomes lipid soluble and therefore is able to readily cross the blood-brain barrier'*. Midazolam is principally cleared by hepatic enzymes with a mean elimination half-life of 2 hours in healthy subjects'. It can be administered as a bolus and does not cause significant haemodynamic or respiratory changes at a dose of 0.2 mg/kg"*'2*20~23.
The pharmacological properties of midazolam are typical of the benzodiazepine class, namely: hypnotic, anxiolytic, muscle relaxant and anticonvulsant effects. The anticonvulsant action is thought to be due to its enhancement of y-aminobutyric acid (GABA) which as the main inhibitory neurotransmitter in the brain causes hyperpolarisation of the cells reducing their chance of firing.
In view of this alternative route of administration for a drug with recognised efficacy in status epilepsy, it has been tried on a number of adults with a learning disability who would normally have required large doses of diazepam administered rectally. Two cases are described as follows.
Case 1 A 25year-old female with idiopathic generalised epilepsy and a moderate learning disability was admitted to a specialist epilepsy centre for assessment of her seizure disorder. Seizures included absences and tonicclonic events, the latter lasting up to 1 hour without emergency intervention. They were also characterised by marked central cyanosis, necessitating administration of oxygen. Prior to admission, the frequency of tonic-clonic events was between two and six per day with rectal diazepam being given on each occasion, followed by post-ictal sleep lasting anything up to 5 hours. The situation was further complicated by a local social services policy which prevented administration of rectal medication by carers at the day centre attended by the patient. As a consequence, the patient's father was contacted at his nearby workplace on a daily basis, so that he could administer the diazepam.
On admission the patient was lethargic, sedated and in a wheelchair. She was taking optimal doses of lamotrigine and controlled release sodium valproate which were not altered, but rectal diazepam was replaced by intranasal midazolam for the management of prolonged seizures.
Within 2 weeks of commencing intranasal rnidazolam and concomitant cessation of rectal diazepam, she was alert, bright, no longer required a wheelchair and was even playing football. By using midazolam, tonicclonic seizures were aborted within 2-5 minutes and a full and uneventful recovery effected within 10-20 minutes, allowing her to continue her daily activities.
The improvement has continued following her dis-an effective rescue medication for severe epilepsy 511 charge, with staff at the day centre administering the midazolam intranasally. It is interesting to note that she only required midazolam on two to three occasions per week as opposed to up to six times daily for rectal diazepam.
Case 2
A 20-year-old male student with a moderate to severe learning disability was attending a college for further education. He had experienced complex partial and tonic-clonic seizures since childhood. The latter were prolonged and he frequently became centrally cyanosed, requiring oxygen. He was taking a combination of lamotrigine, controlled release sodium valproate and topiramate, but still experienced at least one severe tonic-clonic seizure per week. He required 30 mg of rectal diazepam and occasionally rectal paraldehyde for the control of prolonged seizures; frequently sleeping for up to 4 hours following these events and rescue drug administration. A major precipitant of tonic-clonic events appeared to be excitement and, as a consequence, college excursions and community placements were frequently hindered leading to the eventual denial of access to social experiences.
Intranasal midazolam, in this patient, took effect within 3-4 minutes; a full recovery ensuing within lO-15 minutes.
DISCUSSION
There have been a number of studies comparing doses and serum concentrations of midazolam and the conclusion has been that a dose of intranasal midazolam of 0.2 mg/kg, as for the intravenous route, is the optimum dose in children. Separate studies have confirmed that in most patients, within 10 minutes of receiving this dose, sedation is induced when the drug is being used in anaesthetic practice'***' and EEG monitored seizure& l6 are terminated when it is being used to treat epilepsy.
Local effects such as sneezing and coughing are dose related and occur less frequently at 0.2 mg/kgZ3. Patients administered this drug intranasally whilst awake have noted discomfort or an odd sensation at the back of their throats but all who could compare between intranasal, intravenous or rectal routes of administration preferred the intranasal route5. The only condition associated with failure is the presence of an upper respiratory tract infection with copious nasal secretions.
A comparative study of the plasma concentration of intravenous, intranasal and rectal administered midazolam of 0.2 mg/kg has shown that both intravenous and intranasal routes avoid first pass metabolism and achieve similar concentrations at 45 minutes, whereas rectal administration leads to a significantly lower peak plasma concentration'O.
Because medically untrained carers are usually expected to administer the drug, a simple and safe method needs to be employed. At present the preparation used is the intravenous midazolam, 10 mg in 2 ml, solution. The equipment required for administration is a 2.5 ml syringe and a neonatal nasogastric feeding tube. The administration of the drug is via the intranasal route so an accumulation of air in the system is not a problem. In our experience it is not appropriate to determine the dose per kilogram in adults although we do advise that patients below 50 kg receive a dose of 5 mg whilst for those over 50 kg a dose of 10 mg is used.
CONCLUSION
In both cases described, the patients' parents were trained in the use of intranasal midazolam and were able to administer it with good effect. Non-professional care staff were also trained in its use and were comfortable with its administration. The rapid recovery rate facilitated by using midazolam as an alternative to diazepam obviously had significant implications for both patients in the cases described, affecting their education, social development and quality of life.
Initial evaluation of intranasal midazolam seems to show that it has significant advantages over rectal diazepam. Midazolam has a much shorter half-life and a smaller volume of distribution than diazepam and so does not accumulate in the body. Due to these differences the recovery time following administration is shorter. The route of administration is also significantly more acceptable to both patients and carers providing a more dignified method of rescue medication delivery.
Further refinement of the drug and the delivery system are required to make this a universally acceptable practice. Midazolam is currently licensed as an anaesthetic agent with known anticonvulsant effects; it is, however, unlicensed for the intranasal route.
No local effects have been noted in the individuals treated thus far, but the low pH of midazolam could potentially damage the mucosal surface if used repeatedly over several hours. The current volume of l-2 ml does not cause any problems but might be better absorbed if delivered in a nasal spray which would also decrease the required dose. A nasal spray would also reduce the risk of injury to medically untrained staff who sometimes find breaking the glass vial a difficult task. One requirement before this treatment can even be considered is that nursing staff and carers must be trained in the technique so that the delivery is both safe and effective.
As an alternative emergency treatment to rectal di- 
